ストックスクリーナーアプリを入手
1.58
1.56%
-0.025
前日終値:
$1.605
開ける：
$1.5
24時間の取引高:
23,680
Relative Volume:
0.35
時価総額：
$32.34M
収益：
-
当期純損益:
$-61.06M
株価収益率:
-0.1103
EPS:
-14.3261
ネットキャッシュフロー:
$-59.30M
1週間 パフォーマンス:
+8.97%
1か月 パフォーマンス:
+21.54%
6か月 パフォーマンス:
-47.16%
1年 パフォーマンス:
-83.10%
1日の値動き範囲:
$1.50
$1.70
1週間の範囲:
$1.41
$1.78
52週間の値動き範囲:
$1.06
$12.26
Boundless Bio Inc Stock (BOLD) Company Profile
BOLD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.585 | 32.34M | 0 | -61.06M | -59.30M | -14.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.53 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.41 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.46 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.48 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.49 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-04-22 | 開始されました | Guggenheim | Buy |
| 2024-04-22 | 開始されました | Leerink Partners | Outperform |
| 2024-04-22 | 開始されました | Piper Sandler | Overweight |
Boundless Bio Inc (BOLD) 最新ニュース
New Strong Sell Stocks for May 1st - The Globe and Mail
Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace
Boundless Bio’s 2024 Financial Results and Strategic Progress - MSN
Boundless Bio stock plunges to 52-week low of $1.41 - Investing.com Australia
Boundless Bio to Participate in the Needham Virtual Healthcare Conference - TradingView
Boundless Bio stock plunges to 52-week low of $1.41 By Investing.com - Investing.com UK
Boundless Bio plans $14.5M stock sale via Jefferies By Investing.com - Investing.com Australia
Boundless Bio plans $14.5M stock sale via Jefferies - Investing.com India
Boundless Bio Inc Files For Mixed Shelf Of Up To $400 MillionSEC Filing - MarketScreener
Boundless Bio Inc. (BOLD) reports earnings - Quartz
Boundless Bio Reports Fourth Quarter And Full Year 2024 Financial Results And Business Highlights - Marketscreener.com
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - The Manila Times
Boundless Bio's $152M War Chest Fuels Breakthrough Cancer Drug Development - Stock Titan
A quarter of cancer patients don’t respond to targeted therapies. This biotech wants to help them. - pharmaphorum
Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation - Yahoo Finance
What Will Boundless Bio Reveal at the Leerink Conference? CEO Set for Key Presentation - StockTitan
J&J vet jumps to Affinia—Chutes & Ladders - Fierce Biotech
Francisco Ballester to retire from Sandoz - BioCentury
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer -February 03, 2025 at 10:00 am EST - Marketscreener.com
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Oncology Drug Development Expert Behind TRK Inhibitors Joins Boundless Bio as CMO - StockTitan
Beta Bionics targets IPO of up to $120M - BioWorld Online
Apellis COO stepping down to take first CEO job—Chutes & Ladders - Fierce Biotech
Neomorph Announces Appointment of Dr. Klaus Wagner, M.D., Ph.D. as Chief Medical Officer - BioSpace
Neomorph Appoints Dr. Klaus Wagner as Chief Medical Officer - citybiz
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
January Effect Builds Up Momentum: 5 Small-Cap Stocks to Buy - MSN
Terremoto Biosciences Appoints James Christensen, Ph.D., as President and Head of Research & Development - Business Wire
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Layoffs Continued Across Biopharma in 2024 - BioSpace
The Escalator: Boundless Bio, Intelliguard, Klick Health and more - MM+M Online
Guggenheim Downgrades Boundless Bio (BOLD) - MSN
Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO - BioPharma Dive
Genesis hires Shifeng Pan as CSO, names Paul Friedman chair - BioCentury
Boundless Bio, Inc. Changes to Management Team - Marketscreener.com
Boundless Bio Won't Advance Cancer Treatment Trial, Executives to Step Down - MarketWatch
Boundless Bio Announces Pipeline and Leadership Updates - The Manila Times
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
Vertex Global reports ten IPOs, acquisitions worldwide in 2024 - Tech in Asia
Boundless Bio, Inc. (BOLD) Loses -19.52% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Amgen picks prolific biotech founder Chang as new top scientist - BioPharma Dive
Amgen names Stanford geneticist and biotech founder to CSO post - Endpoints News
Science Spotlight: How extrachromosomal DNA drives cancer - BioCentury
Extrachromosomal DNA acts as joker for cancer cells - BioWorld Online
Boundless Bio Inc (BOLD) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.44%
大文字化:
|
ボリューム (24 時間):